Nano24

The cytokine storm is the most severe complication of a wide range of pulmonary and systemic diseases with an urgent unmet need, leading to more than 60M patients with 15M deaths per year. Utilising two breakthroughs, CD24 (the drug), and Exosomes (the carrier), Nano24 has developed the next generation of immunomodulators proving to solve the cytokine storm. EXO- CD24 is the first clinically tested, IP protected, exosomal based drug derived from genetically manipulated human embryonic cells. As a platform, EXO-CD24 has the potential to address many unmet indications, such as ARDS, SEPSIS, Cardiogenic Shock and many more. As a first step, Nano24 focuses on the ARDS market, which has no medical therapy, is responsible for 10-20% general admissions to ICU and causes 1.2 million deaths per year (similar to the world wide annual deaths from car accidents). After clinical trials phases Ib+IIa and IIb (dose finding study), the results showed extremely high success, with no deaths caused by the cytokine storm, duration of hospitalisation dramatically reduced and no any side effects. Nano24 (formerly OBCTCD24) was established in June 2020, based on 25 years of knowledge and experience accumulated in the lab of Dr. Shapira and Prof. Arber.

Nano24 has raised $9.5M in total funding across 4 rounds. The company is currently at the Seed stage. Key investors include PipelBiz.

Nano24 was founded in 2020 by Prof. Nadir Arber (Founder), Dr. Shiran Shapira (Founder).

Nano24 operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes, Microorganisms, Molecules, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Healthcare.

Nano24 is based in Weizmann St 6, Tel Aviv-Yafo, Israel.